Robust expression of SMN protein observed at day 21 and 65 after single ICV injection confirmed our observation in vitro and this compound was chosen as the lead candidate for further studies and evaluated in a severe mouse model of SMA, allowing a direct comparison of our previously reported PMO(-10-29) [21]. Here, SMN2 is linked to proximal spinal muscular atrophy.